A Case of Cicatricial Alopecia Associated with Erlotinib
Annals of Dermatology
;
: S350-S353, 2011.
Article
in English
| WPRIM
| ID: wpr-165612
ABSTRACT
Erlotinib is a small-molecule tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR). Erlotinib has been used primarily to treat non-small cell lung cancer. In addition to its role in tumor cells, EGFR is also an important regulator of growth and differentiation in the skin and hair. Therefore, EGFR-TKIs have been associated with a number of cutaneous side effects including follicular acneiform eruptions, cutaneous xerosis, chronic paronychia, desquamation, seborrheic dermatitis, and hair texture changes. Herein, we report a rare case of a 61-year-old woman who was treated with erlotinib and experienced cicatricial alopecia.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Paronychia
/
Quinazolines
/
Skin
/
Protein-Tyrosine Kinases
/
Acneiform Eruptions
/
Dermatitis, Seborrheic
/
Carcinoma, Non-Small-Cell Lung
/
Alopecia
/
ErbB Receptors
/
Erlotinib Hydrochloride
Limits:
Female
/
Humans
Language:
English
Journal:
Annals of Dermatology
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS